(b)(4).The incident information provided to abbott vascular, analysis of the returned device, manufacturing records and complaint history for the reported lot were reviewed.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot.Additionally, a review of the complaint history identified no other incidents reported from this lot.The reported difficult clip delivery system (cds) insertion was confirmed via returned device analysis; however, a definitive cause was unable to be determined.The steerable guiding catheter (sgc) hemostasis valve was examined and could be rotated around the braided shaft, indicating that the adhesive bond between the braided shaft and hemostasis valve was broken.Additionally, the hemostasis valve was torn.It is possible that the multiple forced attempts resulted in the observed hemostasis bond break and subsequent detachment as well as the tear in the silicone hemostasis valve; however, this cannot be confirmed.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling.
|
This report is being filed because the steerable guide catheter (sgc) was returned with the hemostasis valve bond broken and valve torn, which has the potential to cause leaks and contribute to patient injury.It was reported that this was a mitraclip procedure to treat functional mitral regurgitation (mr) with a grade of 3-4.After placement of the steerable guide catheter (sgc), the clip delivery system (cds) could not be advanced into the sgc.After several attempts, the cds was able to advance into the sgc with force, and the clip was deployed, successfully completing the procedure with mr reduced to 1.There were no reported adverse patient effects and no reported clinically significant delay in the procedure.There was no additional information provided.The sgc was returned with the hemostasis valve bond broken and valve torn.
|